nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Arthralgia—Docetaxel—ovarian cancer	0.000574	0.000574	CcSEcCtD
Methylphenidate—Chest pain—Docetaxel—ovarian cancer	0.000574	0.000574	CcSEcCtD
Methylphenidate—Myalgia—Docetaxel—ovarian cancer	0.000574	0.000574	CcSEcCtD
Methylphenidate—Pancytopenia—Doxorubicin—ovarian cancer	0.000573	0.000573	CcSEcCtD
Methylphenidate—Nausea—Vinorelbine—ovarian cancer	0.000573	0.000573	CcSEcCtD
Methylphenidate—Dyspepsia—Paclitaxel—ovarian cancer	0.000571	0.000571	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00057	0.00057	CcSEcCtD
Methylphenidate—Conjunctivitis—Epirubicin—ovarian cancer	0.000565	0.000565	CcSEcCtD
Methylphenidate—Decreased appetite—Paclitaxel—ovarian cancer	0.000564	0.000564	CcSEcCtD
Methylphenidate—Dry mouth—Docetaxel—ovarian cancer	0.000561	0.000561	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000561	0.000561	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00056	0.00056	CcSEcCtD
Methylphenidate—Fatigue—Paclitaxel—ovarian cancer	0.000559	0.000559	CcSEcCtD
Methylphenidate—Sweating—Epirubicin—ovarian cancer	0.000557	0.000557	CcSEcCtD
Methylphenidate—Constipation—Paclitaxel—ovarian cancer	0.000555	0.000555	CcSEcCtD
Methylphenidate—Pain—Paclitaxel—ovarian cancer	0.000555	0.000555	CcSEcCtD
Methylphenidate—Haematuria—Epirubicin—ovarian cancer	0.000554	0.000554	CcSEcCtD
Methylphenidate—Confusional state—Docetaxel—ovarian cancer	0.000554	0.000554	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000551	0.000551	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Epirubicin—ovarian cancer	0.00055	0.00055	CcSEcCtD
Methylphenidate—Oedema—Docetaxel—ovarian cancer	0.00055	0.00055	CcSEcCtD
Methylphenidate—Anaphylactic shock—Docetaxel—ovarian cancer	0.00055	0.00055	CcSEcCtD
Methylphenidate—Weight increased—Doxorubicin—ovarian cancer	0.000549	0.000549	CcSEcCtD
Methylphenidate—Epistaxis—Epirubicin—ovarian cancer	0.000548	0.000548	CcSEcCtD
Methylphenidate—Infection—Docetaxel—ovarian cancer	0.000546	0.000546	CcSEcCtD
Methylphenidate—Weight decreased—Doxorubicin—ovarian cancer	0.000546	0.000546	CcSEcCtD
Methylphenidate—Sinusitis—Epirubicin—ovarian cancer	0.000546	0.000546	CcSEcCtD
Methylphenidate—Pneumonia—Doxorubicin—ovarian cancer	0.000541	0.000541	CcSEcCtD
Methylphenidate—Shock—Docetaxel—ovarian cancer	0.000541	0.000541	CcSEcCtD
Methylphenidate—Nervous system disorder—Docetaxel—ovarian cancer	0.000539	0.000539	CcSEcCtD
Methylphenidate—Thrombocytopenia—Docetaxel—ovarian cancer	0.000538	0.000538	CcSEcCtD
Methylphenidate—Infestation NOS—Doxorubicin—ovarian cancer	0.000538	0.000538	CcSEcCtD
Methylphenidate—Drowsiness—Doxorubicin—ovarian cancer	0.000538	0.000538	CcSEcCtD
Methylphenidate—Infestation—Doxorubicin—ovarian cancer	0.000538	0.000538	CcSEcCtD
Methylphenidate—Tachycardia—Docetaxel—ovarian cancer	0.000537	0.000537	CcSEcCtD
Methylphenidate—Feeling abnormal—Paclitaxel—ovarian cancer	0.000535	0.000535	CcSEcCtD
Methylphenidate—Skin disorder—Docetaxel—ovarian cancer	0.000534	0.000534	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000533	0.000533	CcSEcCtD
Methylphenidate—Bradycardia—Epirubicin—ovarian cancer	0.000531	0.000531	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00053	0.00053	CcSEcCtD
Methylphenidate—Haemoglobin—Epirubicin—ovarian cancer	0.000525	0.000525	CcSEcCtD
Methylphenidate—Anorexia—Docetaxel—ovarian cancer	0.000524	0.000524	CcSEcCtD
Methylphenidate—Rhinitis—Epirubicin—ovarian cancer	0.000523	0.000523	CcSEcCtD
Methylphenidate—Conjunctivitis—Doxorubicin—ovarian cancer	0.000523	0.000523	CcSEcCtD
Methylphenidate—Haemorrhage—Epirubicin—ovarian cancer	0.000522	0.000522	CcSEcCtD
Methylphenidate—Pharyngitis—Epirubicin—ovarian cancer	0.000518	0.000518	CcSEcCtD
Methylphenidate—Sweating—Doxorubicin—ovarian cancer	0.000516	0.000516	CcSEcCtD
Methylphenidate—Urinary tract disorder—Epirubicin—ovarian cancer	0.000515	0.000515	CcSEcCtD
Methylphenidate—Urticaria—Paclitaxel—ovarian cancer	0.000515	0.000515	CcSEcCtD
Methylphenidate—Haematuria—Doxorubicin—ovarian cancer	0.000513	0.000513	CcSEcCtD
Methylphenidate—Connective tissue disorder—Epirubicin—ovarian cancer	0.000513	0.000513	CcSEcCtD
Methylphenidate—Abdominal pain—Paclitaxel—ovarian cancer	0.000513	0.000513	CcSEcCtD
Methylphenidate—Body temperature increased—Paclitaxel—ovarian cancer	0.000513	0.000513	CcSEcCtD
Methylphenidate—Urethral disorder—Epirubicin—ovarian cancer	0.000512	0.000512	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000509	0.000509	CcSEcCtD
Methylphenidate—Epistaxis—Doxorubicin—ovarian cancer	0.000507	0.000507	CcSEcCtD
Methylphenidate—Sinusitis—Doxorubicin—ovarian cancer	0.000505	0.000505	CcSEcCtD
Methylphenidate—Visual impairment—Epirubicin—ovarian cancer	0.000503	0.000503	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000501	0.000501	CcSEcCtD
Methylphenidate—Insomnia—Docetaxel—ovarian cancer	0.000497	0.000497	CcSEcCtD
Methylphenidate—Paraesthesia—Docetaxel—ovarian cancer	0.000494	0.000494	CcSEcCtD
Methylphenidate—Erythema multiforme—Epirubicin—ovarian cancer	0.000494	0.000494	CcSEcCtD
Methylphenidate—Bradycardia—Doxorubicin—ovarian cancer	0.000492	0.000492	CcSEcCtD
Methylphenidate—Dyspnoea—Docetaxel—ovarian cancer	0.00049	0.00049	CcSEcCtD
Methylphenidate—Somnolence—Docetaxel—ovarian cancer	0.000489	0.000489	CcSEcCtD
Methylphenidate—Eye disorder—Epirubicin—ovarian cancer	0.000488	0.000488	CcSEcCtD
Methylphenidate—Haemoglobin—Doxorubicin—ovarian cancer	0.000485	0.000485	CcSEcCtD
Methylphenidate—Cardiac disorder—Epirubicin—ovarian cancer	0.000484	0.000484	CcSEcCtD
Methylphenidate—Flushing—Epirubicin—ovarian cancer	0.000484	0.000484	CcSEcCtD
Methylphenidate—Rhinitis—Doxorubicin—ovarian cancer	0.000484	0.000484	CcSEcCtD
Methylphenidate—Dyspepsia—Docetaxel—ovarian cancer	0.000484	0.000484	CcSEcCtD
Methylphenidate—Haemorrhage—Doxorubicin—ovarian cancer	0.000483	0.000483	CcSEcCtD
Methylphenidate—Pharyngitis—Doxorubicin—ovarian cancer	0.000479	0.000479	CcSEcCtD
Methylphenidate—Decreased appetite—Docetaxel—ovarian cancer	0.000478	0.000478	CcSEcCtD
Methylphenidate—Hypersensitivity—Paclitaxel—ovarian cancer	0.000478	0.000478	CcSEcCtD
Methylphenidate—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000477	0.000477	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000475	0.000475	CcSEcCtD
Methylphenidate—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000475	0.000475	CcSEcCtD
Methylphenidate—Fatigue—Docetaxel—ovarian cancer	0.000474	0.000474	CcSEcCtD
Methylphenidate—Angiopathy—Epirubicin—ovarian cancer	0.000474	0.000474	CcSEcCtD
Methylphenidate—Urethral disorder—Doxorubicin—ovarian cancer	0.000473	0.000473	CcSEcCtD
Methylphenidate—Immune system disorder—Epirubicin—ovarian cancer	0.000471	0.000471	CcSEcCtD
Methylphenidate—Mediastinal disorder—Epirubicin—ovarian cancer	0.00047	0.00047	CcSEcCtD
Methylphenidate—Constipation—Docetaxel—ovarian cancer	0.00047	0.00047	CcSEcCtD
Methylphenidate—Pain—Docetaxel—ovarian cancer	0.00047	0.00047	CcSEcCtD
Methylphenidate—Chills—Epirubicin—ovarian cancer	0.000468	0.000468	CcSEcCtD
Methylphenidate—Arrhythmia—Epirubicin—ovarian cancer	0.000466	0.000466	CcSEcCtD
Methylphenidate—Visual impairment—Doxorubicin—ovarian cancer	0.000465	0.000465	CcSEcCtD
Methylphenidate—Asthenia—Paclitaxel—ovarian cancer	0.000465	0.000465	CcSEcCtD
Methylphenidate—Alopecia—Epirubicin—ovarian cancer	0.000461	0.000461	CcSEcCtD
Methylphenidate—Pruritus—Paclitaxel—ovarian cancer	0.000459	0.000459	CcSEcCtD
Methylphenidate—Mental disorder—Epirubicin—ovarian cancer	0.000457	0.000457	CcSEcCtD
Methylphenidate—Erythema multiforme—Doxorubicin—ovarian cancer	0.000457	0.000457	CcSEcCtD
Methylphenidate—Erythema—Epirubicin—ovarian cancer	0.000454	0.000454	CcSEcCtD
Methylphenidate—Malnutrition—Epirubicin—ovarian cancer	0.000454	0.000454	CcSEcCtD
Methylphenidate—Feeling abnormal—Docetaxel—ovarian cancer	0.000453	0.000453	CcSEcCtD
Methylphenidate—Eye disorder—Doxorubicin—ovarian cancer	0.000451	0.000451	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00045	0.00045	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—ovarian cancer	0.000448	0.000448	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—ovarian cancer	0.000448	0.000448	CcSEcCtD
Methylphenidate—Tension—Epirubicin—ovarian cancer	0.000446	0.000446	CcSEcCtD
Methylphenidate—Diarrhoea—Paclitaxel—ovarian cancer	0.000444	0.000444	CcSEcCtD
Methylphenidate—Nervousness—Epirubicin—ovarian cancer	0.000441	0.000441	CcSEcCtD
Methylphenidate—Back pain—Epirubicin—ovarian cancer	0.00044	0.00044	CcSEcCtD
Methylphenidate—Angiopathy—Doxorubicin—ovarian cancer	0.000438	0.000438	CcSEcCtD
Methylphenidate—Muscle spasms—Epirubicin—ovarian cancer	0.000437	0.000437	CcSEcCtD
Methylphenidate—Immune system disorder—Doxorubicin—ovarian cancer	0.000436	0.000436	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000435	0.000435	CcSEcCtD
Methylphenidate—Abdominal pain—Docetaxel—ovarian cancer	0.000435	0.000435	CcSEcCtD
Methylphenidate—Body temperature increased—Docetaxel—ovarian cancer	0.000435	0.000435	CcSEcCtD
Methylphenidate—Chills—Doxorubicin—ovarian cancer	0.000433	0.000433	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—ovarian cancer	0.000431	0.000431	CcSEcCtD
Methylphenidate—Dizziness—Paclitaxel—ovarian cancer	0.000429	0.000429	CcSEcCtD
Methylphenidate—Vision blurred—Epirubicin—ovarian cancer	0.000428	0.000428	CcSEcCtD
Methylphenidate—Alopecia—Doxorubicin—ovarian cancer	0.000427	0.000427	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—ovarian cancer	0.000423	0.000423	CcSEcCtD
Methylphenidate—Ill-defined disorder—Epirubicin—ovarian cancer	0.000422	0.000422	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—ovarian cancer	0.00042	0.00042	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—ovarian cancer	0.00042	0.00042	CcSEcCtD
Methylphenidate—Anaemia—Epirubicin—ovarian cancer	0.00042	0.00042	CcSEcCtD
Methylphenidate—Agitation—Epirubicin—ovarian cancer	0.000418	0.000418	CcSEcCtD
Methylphenidate—Tension—Doxorubicin—ovarian cancer	0.000413	0.000413	CcSEcCtD
Methylphenidate—Vomiting—Paclitaxel—ovarian cancer	0.000412	0.000412	CcSEcCtD
Methylphenidate—Malaise—Epirubicin—ovarian cancer	0.00041	0.00041	CcSEcCtD
Methylphenidate—Rash—Paclitaxel—ovarian cancer	0.000409	0.000409	CcSEcCtD
Methylphenidate—Dermatitis—Paclitaxel—ovarian cancer	0.000409	0.000409	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—ovarian cancer	0.000408	0.000408	CcSEcCtD
Methylphenidate—Vertigo—Epirubicin—ovarian cancer	0.000408	0.000408	CcSEcCtD
Methylphenidate—Syncope—Epirubicin—ovarian cancer	0.000407	0.000407	CcSEcCtD
Methylphenidate—Leukopenia—Epirubicin—ovarian cancer	0.000407	0.000407	CcSEcCtD
Methylphenidate—Back pain—Doxorubicin—ovarian cancer	0.000407	0.000407	CcSEcCtD
Methylphenidate—Headache—Paclitaxel—ovarian cancer	0.000406	0.000406	CcSEcCtD
Methylphenidate—Hypersensitivity—Docetaxel—ovarian cancer	0.000405	0.000405	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—ovarian cancer	0.000404	0.000404	CcSEcCtD
Methylphenidate—Palpitations—Epirubicin—ovarian cancer	0.000402	0.000402	CcSEcCtD
Methylphenidate—Loss of consciousness—Epirubicin—ovarian cancer	0.000399	0.000399	CcSEcCtD
Methylphenidate—Cough—Epirubicin—ovarian cancer	0.000397	0.000397	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—ovarian cancer	0.000396	0.000396	CcSEcCtD
Methylphenidate—Asthenia—Docetaxel—ovarian cancer	0.000394	0.000394	CcSEcCtD
Methylphenidate—Convulsion—Epirubicin—ovarian cancer	0.000394	0.000394	CcSEcCtD
Methylphenidate—Hypertension—Epirubicin—ovarian cancer	0.000392	0.000392	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—ovarian cancer	0.00039	0.00039	CcSEcCtD
Methylphenidate—Pruritus—Docetaxel—ovarian cancer	0.000389	0.000389	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—ovarian cancer	0.000389	0.000389	CcSEcCtD
Methylphenidate—Myalgia—Epirubicin—ovarian cancer	0.000387	0.000387	CcSEcCtD
Methylphenidate—Chest pain—Epirubicin—ovarian cancer	0.000387	0.000387	CcSEcCtD
Methylphenidate—Arthralgia—Epirubicin—ovarian cancer	0.000387	0.000387	CcSEcCtD
Methylphenidate—Agitation—Doxorubicin—ovarian cancer	0.000386	0.000386	CcSEcCtD
Methylphenidate—Anxiety—Epirubicin—ovarian cancer	0.000386	0.000386	CcSEcCtD
Methylphenidate—Nausea—Paclitaxel—ovarian cancer	0.000385	0.000385	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000384	0.000384	CcSEcCtD
Methylphenidate—Discomfort—Epirubicin—ovarian cancer	0.000382	0.000382	CcSEcCtD
Methylphenidate—Malaise—Doxorubicin—ovarian cancer	0.000379	0.000379	CcSEcCtD
Methylphenidate—Dry mouth—Epirubicin—ovarian cancer	0.000378	0.000378	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—ovarian cancer	0.000378	0.000378	CcSEcCtD
Methylphenidate—Syncope—Doxorubicin—ovarian cancer	0.000377	0.000377	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—ovarian cancer	0.000376	0.000376	CcSEcCtD
Methylphenidate—Diarrhoea—Docetaxel—ovarian cancer	0.000376	0.000376	CcSEcCtD
Methylphenidate—Confusional state—Epirubicin—ovarian cancer	0.000374	0.000374	CcSEcCtD
Methylphenidate—Palpitations—Doxorubicin—ovarian cancer	0.000372	0.000372	CcSEcCtD
Methylphenidate—Anaphylactic shock—Epirubicin—ovarian cancer	0.000371	0.000371	CcSEcCtD
Methylphenidate—Oedema—Epirubicin—ovarian cancer	0.000371	0.000371	CcSEcCtD
Methylphenidate—Loss of consciousness—Doxorubicin—ovarian cancer	0.00037	0.00037	CcSEcCtD
Methylphenidate—Infection—Epirubicin—ovarian cancer	0.000368	0.000368	CcSEcCtD
Methylphenidate—Cough—Doxorubicin—ovarian cancer	0.000367	0.000367	CcSEcCtD
Methylphenidate—Shock—Epirubicin—ovarian cancer	0.000365	0.000365	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—ovarian cancer	0.000364	0.000364	CcSEcCtD
Methylphenidate—Nervous system disorder—Epirubicin—ovarian cancer	0.000364	0.000364	CcSEcCtD
Methylphenidate—Dizziness—Docetaxel—ovarian cancer	0.000364	0.000364	CcSEcCtD
Methylphenidate—Thrombocytopenia—Epirubicin—ovarian cancer	0.000363	0.000363	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—ovarian cancer	0.000363	0.000363	CcSEcCtD
Methylphenidate—Tachycardia—Epirubicin—ovarian cancer	0.000362	0.000362	CcSEcCtD
Methylphenidate—Skin disorder—Epirubicin—ovarian cancer	0.00036	0.00036	CcSEcCtD
Methylphenidate—Hyperhidrosis—Epirubicin—ovarian cancer	0.000359	0.000359	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—ovarian cancer	0.000358	0.000358	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—ovarian cancer	0.000358	0.000358	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—ovarian cancer	0.000358	0.000358	CcSEcCtD
Methylphenidate—Anxiety—Doxorubicin—ovarian cancer	0.000357	0.000357	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000355	0.000355	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—ovarian cancer	0.000354	0.000354	CcSEcCtD
Methylphenidate—Anorexia—Epirubicin—ovarian cancer	0.000353	0.000353	CcSEcCtD
Methylphenidate—Dry mouth—Doxorubicin—ovarian cancer	0.00035	0.00035	CcSEcCtD
Methylphenidate—Vomiting—Docetaxel—ovarian cancer	0.00035	0.00035	CcSEcCtD
Methylphenidate—Rash—Docetaxel—ovarian cancer	0.000347	0.000347	CcSEcCtD
Methylphenidate—Dermatitis—Docetaxel—ovarian cancer	0.000346	0.000346	CcSEcCtD
Methylphenidate—Confusional state—Doxorubicin—ovarian cancer	0.000346	0.000346	CcSEcCtD
Methylphenidate—Headache—Docetaxel—ovarian cancer	0.000344	0.000344	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—ovarian cancer	0.000343	0.000343	CcSEcCtD
Methylphenidate—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000343	0.000343	CcSEcCtD
Methylphenidate—Infection—Doxorubicin—ovarian cancer	0.000341	0.000341	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000338	0.000338	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—ovarian cancer	0.000338	0.000338	CcSEcCtD
Methylphenidate—Nervous system disorder—Doxorubicin—ovarian cancer	0.000337	0.000337	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000336	0.000336	CcSEcCtD
Methylphenidate—Insomnia—Epirubicin—ovarian cancer	0.000335	0.000335	CcSEcCtD
Methylphenidate—Tachycardia—Doxorubicin—ovarian cancer	0.000335	0.000335	CcSEcCtD
Methylphenidate—Skin disorder—Doxorubicin—ovarian cancer	0.000333	0.000333	CcSEcCtD
Methylphenidate—Paraesthesia—Epirubicin—ovarian cancer	0.000333	0.000333	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000332	0.000332	CcSEcCtD
Methylphenidate—Dyspnoea—Epirubicin—ovarian cancer	0.000331	0.000331	CcSEcCtD
Methylphenidate—Somnolence—Epirubicin—ovarian cancer	0.00033	0.00033	CcSEcCtD
Methylphenidate—Anorexia—Doxorubicin—ovarian cancer	0.000327	0.000327	CcSEcCtD
Methylphenidate—Nausea—Docetaxel—ovarian cancer	0.000327	0.000327	CcSEcCtD
Methylphenidate—Dyspepsia—Epirubicin—ovarian cancer	0.000326	0.000326	CcSEcCtD
Methylphenidate—Decreased appetite—Epirubicin—ovarian cancer	0.000322	0.000322	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00032	0.00032	CcSEcCtD
Methylphenidate—Fatigue—Epirubicin—ovarian cancer	0.00032	0.00032	CcSEcCtD
Methylphenidate—Constipation—Epirubicin—ovarian cancer	0.000317	0.000317	CcSEcCtD
Methylphenidate—Pain—Epirubicin—ovarian cancer	0.000317	0.000317	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000313	0.000313	CcSEcCtD
Methylphenidate—Insomnia—Doxorubicin—ovarian cancer	0.00031	0.00031	CcSEcCtD
Methylphenidate—Paraesthesia—Doxorubicin—ovarian cancer	0.000308	0.000308	CcSEcCtD
Methylphenidate—Dyspnoea—Doxorubicin—ovarian cancer	0.000306	0.000306	CcSEcCtD
Methylphenidate—Feeling abnormal—Epirubicin—ovarian cancer	0.000306	0.000306	CcSEcCtD
Methylphenidate—Somnolence—Doxorubicin—ovarian cancer	0.000305	0.000305	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000303	0.000303	CcSEcCtD
Methylphenidate—Dyspepsia—Doxorubicin—ovarian cancer	0.000302	0.000302	CcSEcCtD
Methylphenidate—Decreased appetite—Doxorubicin—ovarian cancer	0.000298	0.000298	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000296	0.000296	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—ovarian cancer	0.000296	0.000296	CcSEcCtD
Methylphenidate—Urticaria—Epirubicin—ovarian cancer	0.000295	0.000295	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—ovarian cancer	0.000293	0.000293	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—ovarian cancer	0.000293	0.000293	CcSEcCtD
Methylphenidate—Abdominal pain—Epirubicin—ovarian cancer	0.000293	0.000293	CcSEcCtD
Methylphenidate—Body temperature increased—Epirubicin—ovarian cancer	0.000293	0.000293	CcSEcCtD
Methylphenidate—Feeling abnormal—Doxorubicin—ovarian cancer	0.000283	0.000283	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000281	0.000281	CcSEcCtD
Methylphenidate—Hypersensitivity—Epirubicin—ovarian cancer	0.000273	0.000273	CcSEcCtD
Methylphenidate—Urticaria—Doxorubicin—ovarian cancer	0.000273	0.000273	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—ovarian cancer	0.000271	0.000271	CcSEcCtD
Methylphenidate—Abdominal pain—Doxorubicin—ovarian cancer	0.000271	0.000271	CcSEcCtD
Methylphenidate—Asthenia—Epirubicin—ovarian cancer	0.000266	0.000266	CcSEcCtD
Methylphenidate—Pruritus—Epirubicin—ovarian cancer	0.000262	0.000262	CcSEcCtD
Methylphenidate—Diarrhoea—Epirubicin—ovarian cancer	0.000254	0.000254	CcSEcCtD
Methylphenidate—Hypersensitivity—Doxorubicin—ovarian cancer	0.000253	0.000253	CcSEcCtD
Methylphenidate—Asthenia—Doxorubicin—ovarian cancer	0.000246	0.000246	CcSEcCtD
Methylphenidate—Dizziness—Epirubicin—ovarian cancer	0.000245	0.000245	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—ovarian cancer	0.000243	0.000243	CcSEcCtD
Methylphenidate—Vomiting—Epirubicin—ovarian cancer	0.000236	0.000236	CcSEcCtD
Methylphenidate—Diarrhoea—Doxorubicin—ovarian cancer	0.000235	0.000235	CcSEcCtD
Methylphenidate—Rash—Epirubicin—ovarian cancer	0.000234	0.000234	CcSEcCtD
Methylphenidate—Dermatitis—Epirubicin—ovarian cancer	0.000234	0.000234	CcSEcCtD
Methylphenidate—Headache—Epirubicin—ovarian cancer	0.000232	0.000232	CcSEcCtD
Methylphenidate—Dizziness—Doxorubicin—ovarian cancer	0.000227	0.000227	CcSEcCtD
Methylphenidate—Nausea—Epirubicin—ovarian cancer	0.00022	0.00022	CcSEcCtD
Methylphenidate—Vomiting—Doxorubicin—ovarian cancer	0.000218	0.000218	CcSEcCtD
Methylphenidate—Rash—Doxorubicin—ovarian cancer	0.000216	0.000216	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—ovarian cancer	0.000216	0.000216	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—ovarian cancer	0.000215	0.000215	CcSEcCtD
Methylphenidate—Nausea—Doxorubicin—ovarian cancer	0.000204	0.000204	CcSEcCtD
